Lonnie Moulder’s new biotech play grabs $118M, steering into PhIII and more deals
Serial biotech entrepreneur Lonnie Moulder has scored some big wins along the way, most notably the $9 billion he racked up selling MGI and Tesaro. And now the lead project he’s helping manage as executive chair is making a bold move into Phase III — damn the market turmoil that has largely iced IPOs.
The biotech, based in Waltham, MA with staffers primarily in the US with some clinical ops in China, is called Zenas BioPharma, and the Phase III trial they’ve set up is for obexelimab, a drug they got from Xencor last fall with a mix of equity and milestones.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.